Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04989803 · ClinicalTrials.gov registry record · Phase 1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
A Phase 1 study of Relapsed and/or Refractory B-cell Lymphoma, sponsored by Kite, A Gilead Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 247
- Enrollment target
- 14
- Study locations
NCT04989803 is a Phase 1 study of Relapsed and/or Refractory B-cell Lymphoma that is actively recruiting participants, run by Kite, A Gilead Company. The registered enrollment target is 247 participants. The trial reports 14 study locations across 11 states.
The verdict
NCT04989803, a Phase 1 study of Relapsed and/or Refractory B-cell Lymphoma, is actively recruiting participants, sponsored by Kite, A Gilead Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 247 participants
- Enrollment target
- 14
- Study locations
Study Summary
The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL KITE-363
- BIOLOGICAL KITE-753
Study Locations (14)
Other
- Universitatsklinikum Wurzburg - Würzburg
- Academisch Medisch Centrum - Amsterdam
- King's College Hospital - London
New York
- Columbia University Irving Medical Center - New York
- University of Rochester Medical Center - Rochester
Arizona
- Banner MD Anderson Cancer Center - Gilbert
California
- Stanford Cancer Institute - Stanford
Georgia
- Northside Hospital - Atlanta
Maryland
- University of MD, Greenebaum Comprehensive Cancer Center - Baltimore
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- The Ohio State University Wexner Medical Center - James Cancer Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2021-10-27 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04989803
The ClinicalTrials.gov registry entry for NCT04989803 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed and/or Refractory B-cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04989803 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Other, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT04989803 about?
NCT04989803 is a clinical study titled "Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma". The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
What is the current status of trial NCT04989803?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 247 participants. The study started on 2021-10-27. Estimated completion is 2027-10.
What conditions does trial NCT04989803 study?
This clinical trial studies the following conditions: Relapsed and/or Refractory B-cell Lymphoma.
What interventions are being tested in trial NCT04989803?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), KITE-363 (BIOLOGICAL), KITE-753 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04989803?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04989803 being conducted?
This trial has 14 study locations across Arizona, California, Georgia, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.